Advertisement
Screener

Arcus Biosciences, Inc. (RCUS) Operating Lease Right-of-Use Assets

2.8 / 5 stars · 68/120 Roast Me

Arcus Biosciences, Inc. Operating Lease Right-of-Use Assets

Arcus Biosciences, Inc. (RCUS) had Operating Lease Right-of-Use Assets of $58.00 million as of 2025-12-31, per its 10-K filed 2026-02-25.

Financial Statements › Balance Sheet › Assets › Assets, Noncurrent

us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-02-25

  • 2025-12-31: Operating Lease, Right-of-Use Asset $58.00M.
  • 2024-12-31: Operating Lease, Right-of-Use Asset $65.00M.
  • 2023-12-31: Operating Lease, Right-of-Use Asset $92.00M.
  • 2022-12-31: Operating Lease, Right-of-Use Asset $100.00M.
Period endOperating Lease, Right-of-Use AssetOperating Lease, Right-of-Use Asset as first filed
2025-12-31$58.00M
10-K · filed 2026-02-25
2024-12-31$65.00M
10-K · filed 2026-02-25
2023-12-31$92.00M
10-K · filed 2025-02-25
2022-12-31$100.00M
10-K · filed 2024-02-21
2022-09-30$102.07M
10-Q · filed 2022-11-02
2022-06-30$104.03M
10-Q · filed 2022-08-03
2022-03-31$102.99M
10-Q · filed 2022-05-09
2021-12-31$105.00M
10-K · filed 2023-02-28
$104.97M
10-K · filed 2022-02-23
2021-09-30$35.55M
10-Q · filed 2021-11-08
2021-06-30$36.14M
10-Q · filed 2021-08-05
2021-03-31$12.24M
10-Q · filed 2021-05-05
2020-12-31$12.78M
10-K · filed 2022-02-23

Similar stocks

Stock NameCountryMarket CapPE Ratio
Dyne Therapeutics, Inc. (DYN)United States$3.084B-7.09
Arcutis Biotherapeutics, Inc. (ARQT)United States$3.303B115.47
Enliven Therapeutics, Inc. (ELVN)United States$3.307B-35.07
Amylyx Pharmaceuticals, Inc. (AMLX)United States$3.361B-13.15
IDEAYA Biosciences, Inc. (IDYA)United States$3.540B-20.52
Organon & Co. (OGN)United States$3.603B17.03
PRECIGEN, INC. (PGEN)United States$2.757B-12.94
NewAmsterdam Pharma Co N.V. (NAMS)$2.719B-15.37
Xenon Pharmaceuticals Inc. (XENE)$3.684B-14.27
MBX Biosciences, Inc. (MBX)United States$2.664B-25.36